GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten public offering of 30,303,050 shares of common stock at a price to the public of $1.65 per share for gross proceeds of $50 million, before deducting the underwriting discounts and offering expenses. In connection with this offering, Novavax has granted the underwriters a 30-day option to purchase up to an additional 4,545,457 shares of its common stock. If the underwriters exercise this option in full, Novavax will have sold 34,848,507 shares of its common stock.
Novavax Prices Public Offering of Common Stock
Apr 12, 2018
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers